论文部分内容阅读
很多抗癌金属药物是以核酸为靶标。阐明小分子与核酸之间的相互作用对筛选具有高效选择性和低毒副作用的抗癌药物有重要意义。近年来,开发新型的具有对核酸序列特异性识别能力的抗癌药物己成为本领域的研究热点。稀土离子具有良好的磁学、光学、电学特性和配位能力,使稀土配合物成为新型药物试剂。然而,稀土离子在中性条件下易水解的特性极大地阻碍了稀土配合物对核酸分子识别的研究。近年来在近生理条件下合成的一系列镧系氨基酸配合物具有结构稳定、溶解性好等优点,解决了镧系离子易水解的问题。本文总结了目前关于镧系氨基酸配合物与核酸的相互作用及其序列选择性等方面的研究进展。
Many anticancer metal drugs target nucleic acids. The elucidation of the interaction between small molecules and nucleic acids is of great significance in the screening of anticancer drugs with high selectivity and low toxic side effects. In recent years, it has become a research hotspot in the field to develop a new type of anticancer drug that has the ability to specifically recognize nucleic acid sequences. Rare earth ions have good magnetic, optical, electrical properties and coordination ability, the rare earth complexes become a new type of pharmaceutical reagents. However, the ability of rare earth ions to be easily hydrolyzed under neutral conditions greatly hinders the study of the recognition of nucleic acid molecules by rare earth complexes. In recent years, a series of Lanthanide amino acid complexes synthesized under near physiological conditions have the advantages of stable structure, good solubility and the like, and solve the problem that lanthanide ions are easily hydrolyzed. This article summarizes the current research progress on the interaction of lanthanide amino acids with nucleic acids and their sequence selectivity.